OBJECTIVES: The aim of this study is to evaluate the predictive impact of cigarette smoking on treatment outcomes of EGFR-tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma patients with activating EGFR mutations. METHODS: We retrospectively analyzed 222 consecutive recurrent or unresectable lung adenocarcinoma patients who harbored activating EGFR mutations (exon 19 deletion or exon 21 L858R) and had received gefitinib or erlotinib. Detailed smoking histories were obtained from all patients according to a standard protocol. RESULTS: Of 222 EGFR-mutated patients, 65.3% were never-smokers, 19.8% were smokers with < 30 pack-years, and 14.9% were smokers with ≥ 30 pack-years smoking dosage. The disease control rate (DCR) and objective re...
mutation positive (M+) lung adenocarcinoma (ADC) to determine their impact on survival in patients ...
The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for add...
PURPOSE: Recent studies reported that clinical responsiveness to gefitinib was associated with somat...
AbstractBackgroundThe strong association between smoking history and the presence of epidermal growt...
[[abstract]]Purpose: In the current targeted therapy era, information on the effect of smoking in ep...
PURPOSE: This study aimed to determine the dose effect of smoking on the mutational frequency and sp...
PURPOSE: Active tobacco smoking has been associated with the incidence of epidermal growth factor re...
<div><p>Objectives</p><p>This purpose of this study was to examine clinical-pathologic factors – par...
OBJECTIVES: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth ...
Purpose: This study evaluated the mutational profile of epidermal growth factor receptor (EGFR) and ...
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) ben...
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) ben...
AbstractIntroductionEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatmen...
Purpose ;We examined the impact of different epidermal growth factor receptor (EGFR) mutations and c...
BACKGROUND/AIM: Gefitinib and erlotinib were shown to be particularly effective in a clinically sele...
mutation positive (M+) lung adenocarcinoma (ADC) to determine their impact on survival in patients ...
The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for add...
PURPOSE: Recent studies reported that clinical responsiveness to gefitinib was associated with somat...
AbstractBackgroundThe strong association between smoking history and the presence of epidermal growt...
[[abstract]]Purpose: In the current targeted therapy era, information on the effect of smoking in ep...
PURPOSE: This study aimed to determine the dose effect of smoking on the mutational frequency and sp...
PURPOSE: Active tobacco smoking has been associated with the incidence of epidermal growth factor re...
<div><p>Objectives</p><p>This purpose of this study was to examine clinical-pathologic factors – par...
OBJECTIVES: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth ...
Purpose: This study evaluated the mutational profile of epidermal growth factor receptor (EGFR) and ...
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) ben...
Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) ben...
AbstractIntroductionEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatmen...
Purpose ;We examined the impact of different epidermal growth factor receptor (EGFR) mutations and c...
BACKGROUND/AIM: Gefitinib and erlotinib were shown to be particularly effective in a clinically sele...
mutation positive (M+) lung adenocarcinoma (ADC) to determine their impact on survival in patients ...
The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for add...
PURPOSE: Recent studies reported that clinical responsiveness to gefitinib was associated with somat...